NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $5.68 +0.08 (+1.43%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.59▼$5.7050-Day Range$5.16▼$5.8652-Week Range$4.71▼$12.43Volume1.01 million shsAverage Volume1.78 million shsMarket Capitalization$812.35 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aurinia Pharmaceuticals alerts: Email Address Aurinia Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside76.1% Upside$10.00 Price TargetShort InterestHealthy6.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth253.33%From $0.15 to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.61 out of 5 starsMedical Sector496th out of 936 stocksPharmaceutical Preparations Industry228th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has received no research coverage in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.08% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 15.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 2.5 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows5 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 253.33% in the coming year, from $0.15 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Read More AUPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUPH Stock News HeadlinesJuly 25 at 5:12 AM | americanbankingnews.comAurinia Pharmaceuticals (AUPH) to Release Earnings on ThursdayJuly 20, 2024 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Below 200-Day Moving Average of $5.99July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 19, 2024 | businesswire.comAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024July 5, 2024 | seekingalpha.comAurinia Pharmaceuticals Appears UndervaluedJune 14, 2024 | businesswire.comAurinia Announces 2024 Annual General Meeting ResultsJune 5, 2024 | businesswire.comAurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024May 30, 2024 | businesswire.comAurinia Will Attend 2024 Jefferies Global Healthcare ConferenceJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 26, 2024 | finance.yahoo.comShareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past weekMay 14, 2024 | finance.yahoo.comAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024May 14, 2024 | businesswire.comAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024May 13, 2024 | stocknews.comTop 4 Pharma Stocks to Consider This MonthMay 9, 2024 | finance.yahoo.comAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024May 7, 2024 | businesswire.comAurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder ValueMay 7, 2024 | businesswire.comAurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)See More Headlines Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/27/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$13.00 Low Stock Price Target$8.00 Potential Upside/Downside+76.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E Ratio37.87 P/E GrowthN/ANet Income$-78,020,000.00 Net Margins-32.69% Pretax Margin-32.24% Return on Equity-15.06% Return on Assets-10.57% Debt Debt-to-Equity Ratio0.19 Current Ratio5.60 Quick Ratio5.05 Sales & Book Value Annual Sales$175.51 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book2.16Miscellaneous Outstanding Shares143,020,000Free Float136,529,000Market Cap$812.35 million OptionableOptionable Beta1.44 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 54)President, CEO & Director Comp: $1.34MMr. Joseph M. Miller CPA (Age 50)Chief Financial Officer Comp: $791.92kMr. Matthew Maxwell Donley M.B.A. (Age 55)Executive Vice President of Operations & Strategy Comp: $811.82kMr. Stephen P. Robertson (Age 42)Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $739.68kDr. Volker Knappertz D.Sc. (Age 59)M.D., Executive Vice President of Research & Development Comp: $742.85kAndrea Levin ChristopherHead of the Corporate Communications & Investor RelationsMr. Fran LynchVice President of SalesMr. Michael R. Martin (Age 52)Chief Business Officer Comp: $350.57kMs. Sue EvansSenior Vice President of Global Regulatory AffairsMr. Scott Habig (Age 64)Chief Commercial Officer More ExecutivesKey CompetitorsIGM BiosciencesNASDAQ:IGMSY-mAbs TherapeuticsNASDAQ:YMABCryoportNASDAQ:CYRXAmarinNASDAQ:AMRNMyovant SciencesNYSE:MYOVView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 77,510 shares on 7/26/2024Ownership: 0.342%DekaBank Deutsche GirozentraleSold 11,608 shares on 6/4/2024Ownership: 0.005%Cetera Advisors LLCBought 9,547 shares on 5/24/2024Ownership: 0.042%Virtu Financial LLCBought 15,591 shares on 5/20/2024Ownership: 0.011%Walleye Trading LLCBought 200 shares on 5/17/2024Ownership: 0.000%View All Institutional Transactions AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $8.99 at the start of the year. Since then, AUPH stock has decreased by 36.8% and is now trading at $5.68. View the best growth stocks for 2024 here. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.14. The biotechnology company earned $50.30 million during the quarter, compared to analyst estimates of $46.30 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 15.06% and a negative net margin of 32.69%. Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' top institutional investors include Bank of New York Mellon Corp (0.34%). Insiders that own company stock include Peter Greenleaf, Joseph M Miller, Stephen P Robertson, George M Milne Jr, David RW Jayne, Robert Bindert Huizinga, Neil Solomons, Michael Robert Martin and Jill Leversage. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA) and Exelixis (EXEL). This page (NASDAQ:AUPH) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
